Cooling Off? Early Intervention? Very Early Intervention? Steve Holmberg Sussex Cardiac Centre.

Slides:



Advertisements
Similar presentations
Patient Oriented Therapy Non STE ACS
Advertisements

Unstable angina and NSTEMI
A ggrastat- Phase of the AGGRASTAT to ZOCOR (A to Z) Trial Comparison of the safety and efficacy of unfractionated heparin versus enoxaparin in combination.
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
Keith A A Fox Royal Infirmary & University of Edinburgh CURE and PCI-CURE.
Optimal Timing of PCI in ACS Patrick Hildbrand. Trends and Prognosis in ACS Furman MI, JACC 2001, 37: Hospital 1 year.
Timing of Intervention in Patients with Acute Coronary Syndromes (TIMACS) AHA, 2008.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
VA NQWISH Veterans Affairs Non-Q Wave Infarction Strategies In-Hopsital Trial.
“Adjunctive Therapy” Non ST segment elevation ACS Dr M R Thomas King’s College Hospital. Advanced Angioplasty 2002.
Stanford ACS Guidelines 2003 David P. Lee, M.D. John S. Schroeder, M.D. *Donald Schreiber, M.D. Division of Cardiovascular Medicine and *Department of.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.
Optimal Management of ACS Invasive vs Conservative Strategy
Myocardial Infarction
Download from Slide 1 AGGRASTAT ® † (tirofiban, MSD) to ZOCOR ™ † (simvastatin, MSD) (A to Z) Trial Results from the AGGRASTAT.
TACTICS-TIMI 18 Economics & HRQOL Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
CRUSADE: A National Quality Improvement Initiative CRUSADE: A National Quality Improvement Initiative Can Rapid Risk Stratification of Unstable Angina.
Slide 1 AGGRASTAT ™ † (tirofiban, MSD) to ZOCOR ™ † (simvastatin, MSD) (A to Z) Trial Results from the AGGRASTAT Phase † Trademarks of Merck & Co., Inc.,
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Prospective, Randomized Evaluation of Immediate Versus Deferred Angioplasty in Patients with High Risk Acute Coronary Syndromes RK Riezebos 1, E Ronner.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,
TARGET and TACTICS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
The INT egrelin and E noxaparin R andomized assessment of A cute C oronary syndrome Treatment T rial Sponsored by the Canadian Heart Research Centre, Key.
TCT Presentation October 2006 Outcomes in Elderly Patients Undergoing PCI Treated with Bivalirudin Monotherapy versus Glycoprotein IIb/IIIa Inhibitors.
Acute Coronary Syndromes. Learning outcomes To understand the clinical spectrum of coronary disease To recognise different presentations of the disease.
Acute Coronary Syndrome David Aymond, MD. ACS Definition: Myocardial ischemia typically due to atherosclerotic plaque rupture  Coronary thrombosis ACS.
Acute Coronary Syndromes in West Hertfordshire Masood Khan.
TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.
Antiplatelet Interventions in Acute Coronary Syndromes.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
LESSON 1 LESSON 1 Establishment of:
MICHELANGELO: OASIS 5 Women’s Substudy Dr. Eva Swahn Department of Cardiology, Heart Centre, University Hospital, Linköping Sweden Disclosure Funded by.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
The Benefit of an Invasive Strategy in Women Versus Men with Non-ST-Elevation ACS: A Collaborative Meta-Analysis of Randomized Trials Michelle O’Donoghue,
Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy BMS & Sanofi Aventis Sponsored.
Date of download: 5/28/2016 From: Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Support for implementing NICE guidance: Unstable angina and NSTEMI Unstable angina and NSTEMI, CG94, rd Edition March 2014.
Invasive Versus Conservative Strategy in Patients Aged 80 years or Older with NSTEMI or Unstable Angina(After Eighty study) Nicolai Tegn, Michael Abdelnoor,
1 Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial N Engl J Med 2001;344:
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Antiplatelet therapy for STEMI
The European Society of Cardiology Presented by Dr. Saman Rasoul
Unstable Angina and Non–ST Elevation Myocardial Infarction
Antiplatelet Therapy and Secondary Prevention
This series of slides highlights a report on a symposium at the European Society of Cardiology Congress held in Munich, Germany from August 28 to September.
European Heart Association Journal 2007 April
Late Breaking Clinical Trials
Section D: Clinical trial update: GP IIb/IIIa inhibition
Invasive versus conservative treatment in unstable coronary syndromes
TIMI IIIA Protocol Design 391 Patients with Unstable Angina / NQWMI
The European Society of Cardiology Presented by RJ De Winter
RIDDLE-NSTEMI Trial design: Patients with NSTEMI were randomized to either immediate (within 2 hours) intervention or delayed (within 72 hours) intervention.
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
Presentation transcript:

Cooling Off? Early Intervention? Very Early Intervention? Steve Holmberg Sussex Cardiac Centre

NO CONFLICT OF INTEREST TO DECLARE

Invasive Strategy in ACS - is there still a debate?  ICTUS No benefit of invasive strategy out to 5 years Intervention rates high in the ‘conservative’ arm No penalty for early intervention Invasive strategy may facilitate early discharge and obviate readmission

The Evidence for Intervention  3 Landmark Trials FRISC II (2457) RITA-3 (1810) TACTICS-TIMI 18 (2220)

FRISC II  Death/MI 6/12 INVCON (PCI at 96 hrs)  Revasc71%9%  Endpoint9.4%12.1%  Death1.9%2.9%  MI7.5%9.2%

RITA-3  Death/MI/Refractory Angina 4/12 INVCON (PCI at 72hrs)  Endpoint9.6%14.5% (Driven by refractory angina) But:  Death/MI at 5 years16.6%20.0%

TACTICS-TIMI 18 Death/MI/Re-Hospitalisation at 6/12 INV CON (PCI at 24 hrs)  Endpoint15.9%19.4%  Death3.3%3.5%  MI4.8%6.9%  Rehosp11.0%13.7%  Revasc60%36%  TIMI Risk %30.6% %20.3% %11.8%

TIMI Risk Score  History Age65 or older Risk Factors3 or more Known CAD50%+ stenosis Aspirin useWithin 7 days  Presentation Recent severe angina within 24hrs Raised cardiac markers ST depression 0.5mm or more

The Dilemma Delayed Benefit: Plaque passification with medical treatment followed by intervention on more stable plaque Risk: Events that may occur while waiting Early Benefit: Prevention of early events that may have occurred while waiting Rapid diagnosis and early discharge Risk: Potential for early hazard because of intervention on unstable plaque with fresh thrombus

ISAR-COOL  Death/MI (CK-MB >5 x ULN) at 30 days (410) (Clopidogrel 600mg + Heparin + Tirofiban)  Raised Troponin 67%  ST Depression 65% IMMEDIATEDELAYED CATH 2.4hr 86hr ENDPOINT 5.9% 11.6%

ABOARD  Peak Troponin I (352)  TIMI RISK > 2 IMMEDIATEDELAYED CATH 1.2hr 20.5hr ENDPOINT (Death/MI/Revasc at 1/12 - No different)

OPTIMA  Death/MI/Urgent Revasc at 30 days (241)  Raised Troponin 32%  ST Depression 37% IMMEDIATEDELAYED CATH 25 mins! 25 hrs ENDPOINT 60% 39%

OPTIMA  End-point driven by ‘small’ MIs CK 1-2 x ULN  Loading with 300mg Clopidogrel  Considering average times to PCI Extravagant conclusion regarding optimal timing of intervention

TIMACS   Troponin Positive IMMEDIATEDELAYED CATH 14hr 50hr ENDPOINT6/12HR Death/MI/Stroke0.85 (p=0.15 NS) +Ref Isch0.72(p=0.002)

TIMACS  Death/MI/Stroke at 6/12 (3000+)  Troponin Positive EARLYDELAYED CATH 14hr 50hr GRACE Score 140 Low Risk7.76.7(p=0.43 NS) High Risk (p=0.005)

SUMMARY OF KEY TRIALS ISAR COOL EARLY SUPERIOR ABOARD NEGATIVE OPTIMA LATE SUPERIOR TIMACS NEGATIVE EARLY SUPERIOR FOR HIGH RISK GROUP

CONCLUSIONS  Immediate intervention may be beneficial for some Posterior MIs On-going pain Haemodynamic instability  It may be possible to intervene too early Optimal medical therapy is essential Out-of-hours procedures may have inferior outcomes  High risk patients (particularly) should have intervention at the earliest reasonable opportunity

CONCLUSIONS  Get out of bed rarely (for NSTEMI)  Next day is probably fine  The weekend may be too long